Neutrophils and TRAIL: insights into BCG immunotherapy for bladder cancer.
Bladder cancer is a huge economic burden on the healthcare system and is responsible for approximately 5% of all cancer deaths in humans. Mycobacterium bovis BCG-based therapy is the treatment of choice for superficial bladder cancer. Bacillus Calmette-Guerin (BCG) instillation in the bladder results in a massive local inflammatory response that has secondary antitumor properties. Recent studies have demonstrated that neutrophils present in the bladder after BCG instillation release large amounts of the apoptosis-inducing molecule TRAIL, as well as chemokines that recruit other immune cells, suggesting that neutrophils play a key role in the antitumor response to BCG therapy. This review discusses the impact of these findings on the understanding of the antitumor mechanisms underlying BCG-based immunotherapy for bladder cancer.
Simons
Mark P
MP
Department of Urology, 3204 MERF, University of Iowa, 375 Newton Road, Iowa City, IA 52242-1089, USA.
Nauseef
William M
WM
Griffith
Thomas S
TS
D017209:Apoptosis; D051017:Apoptosis Regulatory Proteins / Q000276:immunology / Q000378:metabolism; D001500:BCG Vaccine / Q000276:immunology / Q000627:therapeutic use*; D016207:Cytokines / Q000276:immunology / Q000378:metabolism; D006801:Humans; D007167:Immunotherapy; D009163:Mycobacterium bovis / Q000276:immunology; D018375:Neutrophil Activation; D009504:Neutrophils / Q000276:immunology* / Q000378:metabolism; D053221:TNF-Related Apoptosis-Inducing Ligand / Q000378:metabolism*; D001749:Urinary Bladder Neoplasms / Q000276:immunology* / Q000628:therapy*
D051017:Apoptosis Regulatory Proteins; D001500:BCG Vaccine; D016207:Cytokines; D053221:TNF-Related Apoptosis-Inducing Ligand